PIK3CA and neoplasm: One study found that despite limited efficacy of anti-PD1 monotherapy in mice model bearing PyMT tumor, the co-treatment of a pan-PI3K inhibitor with anti-PD1 antibody leads to a significantly smaller mean tumor volume than with both agents used alone (Sai et al., 2017).